Pavmed Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; comparisons are with FY2019. PAVmed is a pre-revenue medical-device and diagnostics company developing products through its majority-owned Lucid Diagnostics and Solys Diagnostics subsidiaries.
Financial performance and position
| Metric | FY2020 / Dec. 31, 2020 | FY2019 / Dec. 31, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $12.4 million | $7.7 million |
| Research and development expense | $11.0 million | $6.6 million |
| Operating loss | $23.4 million | $14.3 million |
| Net loss attributable to PAVmed common stockholders | $34.6 million; $0.73 per share | $16.7 million; $0.55 per share |
| Cash used in operating activities | $21.9 million | $13.4 million |
| Cash and current assets | $17.3 million cash; $18.9 million current assets | $6.2 million cash; $6.5 million current assets |
| Total assets / total liabilities | $19.8 million / $20.3 million | $7.2 million / $11.9 million |
| Stockholders’ deficit | $0.5 million | $4.6 million |
- Operating expenses rose as the company expanded commercial staffing and increased clinical, engineering, regulatory, and professional-service spending.
- Other expense included $5.3 million of convertible-note fair-value expense and a $6.5 million debt-extinguishment loss. These items significantly increased reported net loss; the filing identifies the fair-value change as non-cash.
- Financing activities provided $33.0 million in cash, including debt and equity proceeds. Year-end convertible-note face principal was $12.8 million, carried at fair value of $14.7 million, in addition to a $0.3 million PPP loan. The notes were repaid or converted after year-end: the remaining November 2019 note converted to shares in January 2021, and the April and August 2020 notes were repaid in cash by March 2, 2021.
- No meaningful gross margin or margin trend is available because reported revenue was zero.
Business developments and changes
- EsoCheck had FDA 510(k) clearance; EsoGuard was commercially available as a laboratory-developed test (LDT). The combined EsoGuard/EsoCheck screening system still required FDA in-vitro-diagnostic authorization. Its clinical studies resumed enrollment after pandemic-related delays. CMS set a Clinical Laboratory Fee Schedule amount of $1,938.10 for 2021–2023, but the filing says no payer had adopted a positive coverage policy; Medicare coverage determination and private-payer reimbursement remained unresolved.
- CarpX received FDA 510(k) clearance in April 2020. The company launched it commercially in August, and the first commercial procedure occurred in December. Revenue contribution was not reported.
- Other products remained in development. Management planned additional EsoCure work and a potential 510(k) submission later in 2021; a PortIO first-in-human study and NextFlo 510(k) submission were also planned. NextFlo was subject to an active strategic-partner/acquirer process.
- Revenue remained zero despite the commercial availability of EsoGuard and EsoCheck and the CarpX launch. Net loss attributable to common stockholders more than doubled, and operating cash use increased year over year.
Outlook, risks, contingencies, and unusual items
- Management expected recurring operating losses and continued reliance on financing. It stated that year-end cash, together with January and February 2021 equity proceeds, was expected to fund operations for one year from issuance of the financial statements. The company raised approximately $55 million gross in those months and subsequently repaid its convertible notes; these proceeds came with substantial share issuance and dilution.
- Key risks include limited commercialization history, inability to generate revenue or secure reimbursement, product adoption and clinical/regulatory uncertainty, competition, reliance on contract manufacturers and a single contract laboratory for EsoGuard, intellectual-property protection, and continued need for capital. COVID-19 disrupted clinical enrollment and physician access and could continue to affect operations and timelines.
- The CWRU license agreement’s commercialization milestone was moved to August 2021 and its payment was eliminated in exchange for a non-refundable fee. If remaining milestones are not met, CWRU may require PAVmed to transfer 80% of its Lucid shares.
- Two legal matters were disclosed: a shareholder voting complaint, for which proposals were ratified in March 2021 and a settlement remained subject to court approval; and a claim by Benchmark Investments seeking up to $1.3 million relating to the December 2020 offerings. PAVmed disputes the latter claim.
- Management reported that a material weakness in financial-reporting controls identified at year-end 2019 was remediated; management assessed controls as effective at December 31, 2020. The auditor issued an unqualified opinion on the financial statements but did not attest to internal-control effectiveness.
Important facts for investors to verify
- Whether commercial testing and CarpX sales generate material revenue, and the associated unit economics and margins.
- Progress toward FDA authorization of the combined EsoGuard/EsoCheck system, trial enrollment and results, and actual Medicare and commercial-payer coverage and payment.
- Cash burn and runway after the 2021 financings, note repayments, and subsequent dilution; confirm the latest cash and fully diluted share count.
- Progress and timing for PortIO, NextFlo, EsoCure, and other pipeline programs, including the NextFlo strategic process.
- Compliance with CWRU license milestones and resolution of the disclosed legal matters.